About
About this blog
The premise this site was built on is that in-depth analysis and rational decision making can help investors enjoy the tremendous potential in the biotech field.
In particular, I believe that the field of monoclonal antibodies is poised for exciting developments and those investors who will recognize the trends and invest in the right players, will be considerably rewarded in the long run.
This blog launched in may 2007 after several years of independent research and coverage of bio-tech stocks.
About Ohad Hammer
I am an independent biotechnology analyst, focusing on small and mid-cap biotech stocks.
I hold a MS in Biotechnology and specialize in targeted therapies for cancer.
Feel free to contact me at ohadhammer AT gmail.com
